BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32889830)

  • 1. Population-based Treatment Patterns and Outcomes for Stage III Non-Small Cell Lung Cancer Patients: A Real-world Evidence Study.
    Yusuf D; Walton RN; Hurry M; Farrer C; Bebb DG; Cheung WY
    Am J Clin Oncol; 2020 Sep; 43(9):615-620. PubMed ID: 32889830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
    Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
    J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Population-based Study of Treatment Patterns and Survival of Patients With De Novo Stage IV Non-Small Cell Lung Cancer.
    Batra A; Yusuf D; Hurry M; Walton RN; Devost N; Farrer C; Cheung WY
    Am J Clin Oncol; 2021 Oct; 44(10):512-518. PubMed ID: 34380947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage III Non-small Cell Lung Cancer Management in England.
    Adizie JB; Khakwani A; Beckett P; Navani N; West D; Woolhouse I; Harden SV
    Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):688-696. PubMed ID: 31514942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.
    Kim HC; Ji W; Lee JC; Kim HR; Song SY; Choi CM; ;
    Cancer Res Treat; 2021 Oct; 53(4):1033-1041. PubMed ID: 33592139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study).
    Jung HA; Sun JM; Lee SH; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2020 Aug; 146():112-119. PubMed ID: 32526601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy.
    Moore S; Leung B; Wu J; Ho C
    J Thorac Oncol; 2019 Aug; 14(8):1430-1439. PubMed ID: 31002953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience.
    Zemanova M; Pirker R; Petruzelka L; Zbozínkova Z; Jovanovic D; Rajer M; Bogos K; Purkalne G; Ceriman V; Chaudhary S; Richter I; Kufa J; Jakubikova L; Zemaitis M; Cernovska M; Koubkova L; Vilasova Z; Dieckmann K; Farkas A; Spasic J; Fröhlich K; Tiefenbacher A; Hollosi V; Kultan J; Kolarová I; Votruba J
    Radiol Oncol; 2020 May; 54(2):209-220. PubMed ID: 32463394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
    Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of treatment and survival among older patients with stage III non-small cell lung cancer.
    Driessen EJM; Schulkes KJG; Dingemans AC; van Loon JGM; Hamaker ME; Aarts MJ; Janssen-Heijnen MLG
    Lung Cancer; 2018 Feb; 116():55-61. PubMed ID: 29413051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada.
    Seung SJ; Hurry M; Walton RN; Evans WK
    Curr Oncol; 2020 Aug; 27(4):e354-e360. PubMed ID: 32905267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013.
    Dickhoff C; Dahele M; de Langen AJ; Paul MA; Smit EF; Senan S; Hartemink KJ; Damhuis RA
    J Thorac Oncol; 2016 Apr; 11(4):566-72. PubMed ID: 26773741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
    Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
    Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment outcome of locally advanced stage IIIA/B lung cancer].
    Cicenas S; Zaliene A; Atkocius V
    Medicina (Kaunas); 2009; 45(6):452-9. PubMed ID: 19605965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
    Friedel G; Budach W; Dippon J; Spengler W; Eschmann SM; Pfannenberg C; Al-Kamash F; Walles T; Aebert H; Kyriss T; Veit S; Kimmich M; Bamberg M; Kohlhaeufl M; Steger V; Hehr T
    J Clin Oncol; 2010 Feb; 28(6):942-8. PubMed ID: 20100967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
    Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
    Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
    Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
    J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.